Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder
2 clinical trials · Condition
◉ Watch Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder
| Record | Firm | Date |
|---|---|---|
| Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders (NCT06672705) | Timothy Voorhees | 2025-06-16 |
| Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (NCT02900976) | Children's Oncology Group | 2017-03-22 |
Track Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder automatically
Every clearance here is in the API, with alerts when new ones post.